Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/14/2018 02/15/2018 02/16/2018 02/20/2018 02/21/2018 Date
54.9(c) 55.99(c) 56.29(c) 54.98(c) 54.55(c) Last
11 446 728 10 099 907 11 731 298 13 466 984 10 284 675 Volume
0.00% +1.99% +0.54% -2.33% -0.78% Change
More quotes
Financials ($)
Sales 2018 41 703 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,41%
Sales 2019 42 345 M
EBIT 2019 14 122 M
Net income 2019 9 629 M
Debt 2019 10 066 M
Yield 2019 3,49%
P/E ratio 2018 17,33
P/E ratio 2019 13,94
EV / Sales2018 4,01x
EV / Sales2019 3,86x
Capitalization 153 B
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Alliances and Healthcare Services.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
03/14Ex-dividend day
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
02:15pMerck to buy virus-based cancer drug firm Viralytics for $394 million
RE
12:27pMERCK AND : to Buy Australia's Viralytics for $394 Million
DJ
10:01aMERCK : and Viralytics Announce Acquisition Agreement, Expanding Merck :’s..
BU
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
AQ
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
AQ
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
RE
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/19BERGENBIO : completes recruitment into first stage of Phase II breast cancer tri..
AQ
02/17MERCK AND : `Really Durable Benefit` Emerging With Bladder Cancer ImmunoTx
AQ
02/17Merck/Pfizers cancer immunotherapy latecomer hits a snag
AQ
More news
Sector news : Pharmaceuticals - NEC
02:39pMERCK : to Invest Additional EUR40 Million in Asia
DJ
02:15pMerck to buy virus-based cancer drug firm Viralytics for $394 million
RE
08:48aNOVARTIS : Builds Up R&D -- WSJ
DJ
08:48aABBVIE : FTC Clout Tested in Suit Versus Drugmaker -- WSJ
DJ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on MERCK AND COMPANY 
MERCK & CO., INC. - 2013
A resistance as obstacle
SELL
More Strategies
Latest Tweets
06:17pWeeks after a financing designed to advance its Cavatak platform to 2020, @Vi..
1
06:12pDow's Merck Jumps On Merger Bandwagon With $394 Million Buy  
05:59pMerck's Keytruda dependence is getting worrisome  
05:27p Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M: Mer.. 
05:15pFor the black CEO of Merck, Ken Frazier, Trump's refusal to unilaterally cond..
10
More tweets
Qtime:313
News from SeekingAlpha
11:49aYOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
07:11aMerck takes out Aussie biotech Viralytics for $394M 
06:37aWALL STREET BREAKFAST : Investors Brace For Fed Minutes 
05:34aMerck to buy Viralytics for $394M 
02/20BIOTECHS : Still Well Placed For More Gains 
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,2 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-0.50%153 359
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
AMGEN3.23%132 827